Open AccessEvaluation of Cyclosporine A with β -TCP in the Treatment of Human Infra bony Defects – A Randomized Controlled Pilot Study
Author(s) -
Jyotsna Amalakara,
Krishnajaneya Reddy,
Haritha Avula,
Ashank Mishra,
Butchibabu Kalakonda,
R.P. Pandey
Publication year - 2017
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2017/23365.9194
Subject(s) - medicine , alkaline phosphatase , cytokine , periodontitis , saline , gastroenterology , dentistry , urology , biochemistry , enzyme , chemistry
Cyclosporine A (CsA), an immunosuppressant, is considered a life saver drug in organ transplant cases. It has also been tested in animal and human studies for periodontal applications as it selectively inhibits T lymphocyte proliferation, Interleukin-2 (IL-2) and other cytokine production, without any effect on T suppressor cells, thereby suppressing the cell mediated immunity and suppressing the inflammation. Inflammatory and immunological responses have been found to be decreased and bone formation is found to be increased in immunosuppressed animals. CsA is also supposed to potentiate osseous regeneration due to increase in the bone alkaline phosphatase levels and a direct activating effect on osteoblasts.